Reclast (Zoledronic Acid) Pediatric Monitoring for Children Under 12

Why Zoledronic Acid Is Used in Children Under 12

Zoledronic acid, marketed as Reclast for adults with osteoporosis, has no FDA-approved indication in pediatric patients. Its use in children under 12 stems almost entirely from the management of osteogenesis imperfecta (OI), a group of genetic disorders that produce brittle bones and recurrent fractures. Severe secondary osteoporosis from chronic glucocorticoid use, immobilization, or oncologic treatment also prompts off-label IV bisphosphonate therapy in this age group.

The 2003 trial by Rauch et al. studied 27 children with OI treated with IV zoledronic acid 0.05 mg/kg every 6 months, showing a lumbar spine areal bone mineral density (aBMD) increase of 24% over 12 months with reduced fracture rates. Because no regulatory body has standardized a pediatric protocol, monitoring practices are extrapolated from adult data (including the HORIZON-PFT trial, N=7,765, which demonstrated a 70% reduction in vertebral fractures with annual IV dosing in postmenopausal women) and from center-specific pediatric OI protocols at institutions like the Shriners Hospital network and Montreal Children's Hospital.

The American Academy of Pediatrics does not publish a standalone bisphosphonate guideline. That gap makes monitoring consistency a genuine clinical challenge.

Pre-Infusion Baseline Assessment

Every child under 12 should complete a structured baseline workup before the first zoledronic acid infusion. Skipping any component raises the risk of preventable adverse events, particularly hypocalcemia and acute kidney injury.

The baseline panel includes serum creatinine with an estimated glomerular filtration rate (eGFR) calculated using the Schwartz formula, which is the standard pediatric renal estimation method. A creatinine clearance below 35 mL/min/1.73 m² is a contraindication per adult labeling, and most pediatric centers apply the same threshold. Serum calcium (corrected for albumin), ionized calcium, phosphate, magnesium, alkaline phosphatase, and 25-hydroxyvitamin D complete the metabolic panel. Children with vitamin D levels below 20 ng/mL should receive repletion before infusion because bisphosphonates amplify the risk of symptomatic hypocalcemia in vitamin D-deficient patients.

A lumbar spine DXA scan provides the baseline bone density reference. In children, results are reported as Z-scores (age- and sex-matched), not T-scores. The International Society for Clinical Densitometry (ISCD) 2019 position states that a Z-score of -2.0 or lower in a child with a clinically significant fracture history meets the definition of pediatric osteoporosis.

Dental examination before IV bisphosphonate initiation is advised by multiple expert consensus groups. While osteonecrosis of the jaw (ONJ) is exceedingly rare in children, the 2014 AAOMS position paper recommends completing any needed invasive dental procedures before starting therapy.

Renal Function Monitoring During Treatment

Kidney safety dominates zoledronic acid monitoring at any age, but pediatric patients present unique challenges. Children have higher ratios of body water to body mass, faster drug clearance, and age-dependent creatinine norms that shift throughout childhood.

The FDA prescribing information for Reclast warns that acute renal failure has occurred in adults, particularly those with pre-existing renal impairment or dehydration. Children cannot always report symptoms of dehydration reliably, which is why pediatric protocols mandate IV hydration with normal saline (10 to 20 mL/kg) before and during the infusion. The infusion itself must run over no fewer than 15 minutes. Running faster than that significantly increases tubular toxicity risk.

Serum creatinine should be rechecked 7 to 14 days after each infusion during the first treatment year. If creatinine rises more than 0.5 mg/dL above baseline or eGFR drops below 35, the next dose is held until renal function recovers. In a retrospective review of 175 children with OI receiving IV bisphosphonates at a single center, clinically significant creatinine elevations occurred in approximately 2% of infusion cycles, nearly all in patients who were inadequately hydrated before the infusion.

After the first year of stable renal function, many centers reduce creatinine checks to pre-infusion only (every 6 months). Urinalysis for proteinuria may be added annually.

Calcium, Phosphate, and Vitamin D Surveillance

Post-infusion hypocalcemia is the single most common metabolic complication in pediatric zoledronic acid therapy. In children under 12, the calcium nadir typically appears between 48 and 72 hours after infusion. The 2013 study by Saraff et al. documented transient hypocalcemia in 21% of children with OI receiving zoledronic acid, with younger children (under 5) at highest risk.

The monitoring schedule for calcium and phosphate looks like this:

• Pre-infusion: Corrected calcium, ionized calcium, phosphate, magnesium, and 25-OH vitamin D
• 24 to 48 hours post-infusion: Ionized calcium (particularly after the first dose or if symptoms develop)
• 72 hours post-infusion: Serum calcium and phosphate if the 24-to-48-hour ionized calcium was below the reference range
• 2 weeks post-infusion: Full metabolic panel if any abnormalities were noted

Supplementation during treatment typically consists of 500 to 1 to 000 mg/day of elemental calcium (adjusted for age and dietary intake) and 400 to 1 to 000 IU/day of vitamin D3. The Endocrine Society's 2011 clinical practice guideline recommends maintaining serum 25-OH vitamin D above 20 ng/mL in all patients receiving antiresorptive therapy. Many pediatric bone specialists target 30 ng/mL or higher.

"Adequate vitamin D repletion before and during IV bisphosphonate therapy in children is non-negotiable," stated Dr. Nick Bishop, Professor of Paediatric Bone Disease at the University of Sheffield, in the 2016 Lancet review of pediatric osteoporosis management.

Phosphate may transiently rise in the first 48 hours post-infusion as bone resorption is acutely suppressed. This rarely requires intervention.

Growth and Skeletal Development Tracking

Bisphosphonates incorporate into the bone matrix and persist for years. In growing children, this raises a theoretical concern about effects on growth plate function and longitudinal growth. The evidence accumulated over two decades is largely reassuring, but monitoring remains mandatory.

Height velocity should be plotted on CDC or WHO growth charts at every clinic visit (every 3 to 6 months). A decline in height velocity of more than 2 cm/year compared to the expected percentile warrants investigation. The 2013 Cochrane review of bisphosphonates for OI (14 trials, 819 participants) found no significant effect on linear growth over treatment periods of 6 to 36 months, though the authors noted that very long-term data past puberty remained limited.

Radiographic monitoring of metaphyseal sclerotic lines ("zebra lines") is sometimes performed. These bands of dense bone at the growth plates confirm drug activity but are not harmful. Their presence does not warrant dose modification.

A follow-up DXA should be performed 12 months after starting treatment. The ISCD recommends using the lumbar spine (L1 to L4) as the primary site in children because hip DXA is unreliable before skeletal maturity. Whole-body-less-head (WBLH) DXA may be added in children over 5 if the clinical question is about total skeletal mass rather than spine-specific density.

Fracture frequency is arguably the most clinically meaningful outcome to track. Parents should keep a fracture log. In children with OI type III or IV, a reduction from 3 to 5 fractures per year to 0 to 1 fracture per year has been the typical treatment response in published cohorts.

Managing the Acute-Phase Reaction

The acute-phase reaction (APR) after zoledronic acid infusion is more common and often more intense in children than in adults. Symptoms include fever (sometimes exceeding 39°C), myalgia, headache, nausea, and irritability. The reaction peaks at 24 to 48 hours and usually resolves within 72 hours.

In the adult HORIZON-PFT trial, APR occurred in 31.6% of patients after the first infusion. Pediatric data suggest rates of 50 to 80% on first exposure, declining to 10 to 20% with subsequent doses. A 2019 retrospective by Baroncelli et al. found that 74% of children with OI experienced fever after the first infusion.

Management is supportive. Acetaminophen (15 mg/kg per dose, every 4 to 6 hours, maximum 75 mg/kg/day) or ibuprofen (10 mg/kg per dose, every 6 to 8 hours) given at the start of infusion and continued for 48 to 72 hours reduces symptom severity. Some centers premedicate with acetaminophen 30 minutes before infusion.

Parents should be counseled that the APR does not indicate allergy or treatment failure. The reaction is less likely on second and subsequent doses.

Monitoring during APR includes temperature checks every 4 to 6 hours at home and contact with the treatment center if fever exceeds 39.5°C or persists beyond 72 hours.

Long-Term Monitoring and Treatment Duration Decisions

There is no consensus on the optimal duration of zoledronic acid therapy in prepubertal children. Most published protocols treat for 2 to 3 years, then reassess based on fracture rate, DXA Z-score trajectory, and clinical severity.

"The decision to continue, pause, or stop bisphosphonate therapy in a growing child should be individualized and re-evaluated at least annually," according to the 2017 Endocrine Society guideline on pediatric bone health.

Unlike adults, where a bisphosphonate "drug holiday" is well-defined (typically after 3 to 5 years), children lack an equivalent evidence base. The concern is that stopping therapy during rapid growth could expose newly formed bone to fracture before it has fully mineralized. Conversely, prolonged treatment accumulates drug in the skeleton with unknown implications for eventual adult bone remodeling.

Annual monitoring after treatment cessation should include:

• DXA lumbar spine Z-score every 12 months for at least 2 years after stopping
• Serum bone turnover markers (CTX or P1NP) at 3, 6, and 12 months post-cessation to confirm that resorption is not rebounding sharply
• Clinical fracture surveillance
• Growth velocity tracking through puberty

If the Z-score drops more than 0.5 standard deviations or fracture rate increases within 12 months of stopping, restarting therapy should be discussed.

Special Populations Within Pediatric Use

Not all children under 12 receiving zoledronic acid have OI. Each secondary indication carries distinct monitoring requirements.

Glucocorticoid-induced osteoporosis: Children on chronic prednisone (0.5 mg/kg/day or higher for 3 months or longer) for conditions like nephrotic syndrome, inflammatory bowel disease, or juvenile dermatomyositis may receive zoledronic acid if vertebral fractures are documented. Blood glucose monitoring should be added because bisphosphonate-induced hypocalcemia can mask or complicate steroid-related glucose dysregulation.

Cerebral palsy with immobilization osteoporosis: These children often have difficulty reporting symptoms. Monitoring for hypocalcemia should rely on lab draws rather than symptom history alone. Seizure risk is elevated if ionized calcium drops below 1.0 mmol/L.

Oncology patients: Children who develop osteoporosis after chemotherapy or bone marrow transplant require coordination between oncology and endocrinology. Renal monitoring is especially important given prior exposure to nephrotoxic agents like cisplatin or methotrexate. The Children's Oncology Group (COG) long-term follow-up guidelines recommend DXA screening 2 years after transplant.

Summary of the Pediatric Monitoring Schedule

| Timepoint | Tests | |---|---| | Baseline (before first infusion) | Creatinine/eGFR, calcium, phosphate, magnesium, 25-OH vitamin D, alkaline phosphatase, DXA spine Z-score, dental exam, height/weight | | Day of infusion | Confirm adequate hydration, recheck creatinine if more than 4 weeks since baseline | | 24 to 72 hours post-infusion | Ionized calcium, temperature monitoring, symptom check for APR | | 7 to 14 days post-infusion | Serum creatinine (first-year infusions) | | 3 months post-infusion | Height velocity, clinical fracture count | | Pre-next infusion (6 months) | Full metabolic panel, creatinine/eGFR, height/weight | | 12 months | DXA lumbar spine Z-score, annual dental exam, growth chart review |

Children with abnormal results at any checkpoint should have the interval shortened to monthly until values stabilize. Serum creatinine rising above 0.5 mg/dL from baseline mandates holding the next infusion until nephrology review is complete.